|
Profiling ER, PR, EGFR and HER2 in Breast Cancer Using Multiplex Tissue Immusta
|
5R44CA123994-03
|
$106,461
|
$106,461
|
JAMES, WILLIAM
|
20/20 GENESYSTEMS, INC.
|
|
Autoantibody Profiling for Serological Detection of Head and Neck Cancer
|
1R43CA139806-01
|
$217,801
|
$217,801
|
Khattar, Nada
|
20/20 GENESYSTEMS, INC.
|
|
Profiling Autoantibodies in Non-small Cell Lung Cancer with Fusion Protein-Peptid
|
1R43CA141963-01
|
$183,927
|
$183,927
|
Khattar, Nada
|
20/20 GENESYSTEMS, INC.
|
|
Novel Small-molecule TNF-a Modulators as Chemoprotective Agents
|
1R43CA141749-01
|
$154,852
|
$154,852
|
SHAW, JIAJIU
|
21ST CENTURY THERAPEUTICS, INC.
|
|
SURVEILLANCE SUPPORT FOR THE NATIONAL CANCER INSTITUTE
|
N02PC513006-006
|
$675
|
$675
|
OLSON, LORAYN
|
ABT ASSOCIATES INC:1105907
|
|
National Tobacco Cessation Collaborative - Youth Tobacco Cessation Collaborative
|
N02PC900209
|
$94,045
|
$94,045
|
UNKNOWN, UNKNOWN
|
Academy for Educational Development
|
|
Targeted Prodrug Chemotherapy for Prostate Cancer
|
1R43CA139677-01A1
|
$159,988
|
$159,988
|
Wu, Jenny
|
ACADUCEUS PHARMACEUTICS, INC.
|
|
Dual Integrin and GRPR Targeted Radiotherapy of Prostate Cancer
|
1R43CA139678-01
|
$100,000
|
$100,000
|
WU, Jenny
|
ACADUCEUS PHARMACEUTICS, INC.
|
|
Health Fotonovela Strips for Spanish Language Newspapers
|
1R43CA135999-01A1
|
$100,001
|
$100,001
|
Matiella, Ana
|
ACMA SOCIAL MARKETING
|
|
Low-Intensity Ultrasound for Treating Tumor Vasculature
|
1R43CA139657-01
|
$145,340
|
$145,340
|
Wood, Andrew
|
ACOUSTIC THERAPEUTICS
|
|
SBIR Topic 264 - (Phase 1) "Development of a Methylation Ratio Assessment Assay"
|
N43CO900048-000
|
$142,932
|
$142,932
|
Challis, Barton
|
ACTIVE MOTIF:1107110
|
|
OPERATION AND MAINTENANCE OF THE BIOLOGICAL DATA PROCESSING SYSTEM
|
N02CM522008-008
|
$652,309
|
$652,309
|
TEKLU, YOHANESS
|
ADDIS INC:1108540
|
|
Data acquisition system for multiplex analysis of color encoded particles
|
1R42CA140109-01
|
$100,231
|
$100,231
|
Gorbovitski, Boris
|
ADVANCED BIOMEDICAL MACHINES, INC.
|
|
Multiplex Gene Expression in Single Cells for Circulating Tumor Cell Detection
|
5R44CA122444-03
|
$547,101
|
$547,101
|
LUO, YULING
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
Development of an anti-PSA IgE to treat prostate cancer
|
1R41CA137881-01
|
$158,851
|
$158,851
|
SCHULTES, BIRGIT
|
ADVANCED IMMUNE THERAPEUTICS, INC.
|
|
Multiplexing Cancer Sample Preparation: Indirect Immunomagnetic Enrichment
|
5R43CA132049-02
|
$144,634
|
$144,634
|
PAMULA, VAMSEE
|
ADVANCED LIQUID LOGIC
|
|
Nanoliter Lab-on-a-Chip for Rapid Parallel Immunoassays
|
5R44CA114993-03
|
$250,000
|
$250,000
|
PAMULA, VAMSEE
|
ADVANCED LIQUID LOGIC
|
|
Clinical study of AdV-tk radiogene therapy for malignant glioma
|
5R44CA107745-05
|
$510,001
|
$510,001
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Antiangiogenic and antitumoral therapy delivered by a dual-expression L. monocyto
|
1R43CA137915-01A1
|
$210,739
|
$210,739
|
Wallecha, Anu
|
ADVAXIS, INC.
|
|
Development and testing of the CAHPS survey for cancer care
|
Y01PC009070
|
$198,000
|
$198,000
|
N/A
|
AGENCY FOR HEALTHCARE RES
|
|
Cancer Screening in Healthy Older Adults: Understanding Quality of Life-Evidence
|
Y01PC009073
|
$100,000
|
$100,000
|
N/A
|
AGENCY FOR HEALTHCARE RES
|
|
Advancing measurement of the patient-centered communication in cancer care
|
Y01PC009080
|
$498,000
|
$498,000
|
N/A
|
AGENCY FOR HEALTHCARE RES
|
|
PROSTATE, LUNG, COLO-RECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL EXPANSION F
|
N01CN075022-063
|
$1,617,215
|
$1,617,215
|
FOUAD, MONA
|
ALABAMA UNIV BIRMINGHAM:1109410
|
|
PRECLINICAL IN VITRO AND IN VIVO SCREENING ASSAYS FOR CANCER PREVENTIVE AGENT DEV
|
N01CN433001-006
|
$4,245,706
|
$4,245,706
|
GRUBBS, CLINTON
|
ALABAMA UNIV BIRMINGHAM:1109410
|
|
FOLATE TESTING
|
N02PC900505
|
$24,750
|
$24,750
|
UNKNOWN, UNKNOWN
|
ALABAMA UNIV BIRMINGHAM:1109410
|
|
PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND OTHER THERAPEUTIC AGENTS
|
N01CM522007-013
|
$255,376
|
$255,376
|
Zhang, Ruiwen
|
ALABAMA UNIV BIRMINGHAM:1109410
|
|
Pharmacology of Cyclophosphamide and Other Alkylators
|
7R01CA016783-34
|
$286,687
|
$286,687
|
LUDEMAN, SUSAN
|
ALBANY COLLEGE OF PHARMACY
|
|
Site-directed Chemotherapy for Breast Cancer using Novel Angiogenesis Inhibitor
|
1R21CA135245-01A1
|
$169,400
|
$169,400
|
MOUSA, SHAKER
|
ALBANY COLLEGE OF PHARMACY
|
|
Experimental Models for Testing Novel Targets for Pancreatic Cancer Cell Invasion
|
5R21CA124931-02
|
$200,970
|
$200,970
|
MOUSA, SHAKER
|
ALBANY COLLEGE OF PHARMACY
|
|
Regulation of MMP-9 mRNA stability and tumor growth by alpha3 beta1 integrin
|
5R01CA129637-02
|
$325,775
|
$325,775
|
DIPERSIO, C
|
ALBANY MEDICAL COLLEGE
|
|
Regulation of Tumor Cell Migration by Mitochondrial Superoxide Dismutase
|
5F32CA134165-02
|
$55,310
|
$55,310
|
Hempel, Nadine
|
ALBANY MEDICAL COLLEGE
|
|
Regulation of Fibronectin Matrix Assembly by uPAR
|
5R01CA058626-16
|
$281,080
|
$281,080
|
MC KEOWN-LONGO, PAULA
|
ALBANY MEDICAL COLLEGE
|
|
Fibronectin Polymerization: Effects on Cell Signaling
|
5R01CA069612-13
|
$271,548
|
$271,548
|
MC KEOWN-LONGO, PAULA
|
ALBANY MEDICAL COLLEGE
|
|
KLF8 Regulation of EMT Tumor Metastasis
|
1R01CA132977-01A2
|
$290,359
|
$290,359
|
ZHAO, JIHE
|
ALBANY MEDICAL COLLEGE
|
|
Old Drugs and New Strategies for Tumor Metastasis
|
5R01CA129598-02
|
$249,000
|
$249,000
|
BRESNICK, ANNE
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Persistent HPV in Women at Risk for Cervix Cancer
|
5U01CA078527-12
|
$590,661
|
$590,661
|
BURK, ROBERT
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
MICROENVIRONMENTS OF INVASION IN HUMAN BREAST TUMORS
|
5R01CA113395-04
|
$286,106
|
$286,106
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Novel Methods for Detecting Cell Interactions in the Tumor Microenvironment
|
5U54CA126511-04
|
$548,821
|
$548,821
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Nck and Crk in VEGF-Induced Endothelial Cells Migration
|
5R01CA107050-05
|
$279,804
|
$279,804
|
COX, DIANNE
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease
|
1R01CA128943-01A2
|
$344,450
|
$344,450
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
PTEN and the molecular genetics of endometrial cancer
|
7R01CA097097-06
|
$334,341
|
$334,341
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
DNA mismatch repair and cancer in murine models
|
5R01CA076329-12
|
$390,439
|
$390,439
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
The Role of Late MMR Proteins in DNA Repair and Cancer
|
5R01CA093484-08
|
$382,706
|
$382,706
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Proton-coupled folate/antifolate transport
|
2R01CA082621-11
|
$526,718
|
$526,718
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Center for AIDS Research (CFAR)
|
5P30AI051519-07
|
$495,337
|
$495,337
|
GOLDSTEIN, HARRIS
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
New Approaches to Prevent or Treat Breast Cancer Metastases
|
5R21CA129470-03
|
$186,750
|
$186,750
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Multiplex approach to DNA methylation assays in exhaled breath condensate
|
5R03CA132145-02
|
$83,000
|
$83,000
|
HAN, WEIGUO
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
EMT, Extravasation and metastasis by N-Cadherin signaling
|
1R01CA135061-01A1
|
$344,450
|
$344,450
|
HAZAN, RACHEL
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
R-Cadherin in Breast Cancer Suppression
|
1R01CA136854-01A1
|
$344,450
|
$344,450
|
HAZAN, RACHEL
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Pro & Anti-Inflammatory Cytokines in Colorectal Cancer
|
5R01CA122654-02
|
$625,384
|
$625,384
|
HO, GLORIA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
Total relevant funding to Cancer for this search: $3,800,016,306
|